首页 | 本学科首页   官方微博 | 高级检索  
     

香杞平脂咀嚼片的降脂作用
引用本文:陆敏,常晓婕,张文晋,刘宁,杨佳美,刘艳华,马学琴,杨建宏,余建强,李凤梅.香杞平脂咀嚼片的降脂作用[J].现代食品科技,2018,34(11):35-40.
作者姓名:陆敏  常晓婕  张文晋  刘宁  杨佳美  刘艳华  马学琴  杨建宏  余建强  李凤梅
作者单位:(1.宁夏医科大学药学院,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004)(2.宁夏回药现代化工程技术研究中心,宁夏回医药协同创新中心,宁夏药物创新与仿制药研究重点实验室,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004)(2.宁夏回药现代化工程技术研究中心,宁夏回医药协同创新中心,宁夏药物创新与仿制药研究重点实验室,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004)(2.宁夏回药现代化工程技术研究中心,宁夏回医药协同创新中心,宁夏药物创新与仿制药研究重点实验室,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004)(2.宁夏回药现代化工程技术研究中心,宁夏回医药协同创新中心,宁夏药物创新与仿制药研究重点实验室,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004)(2.宁夏回药现代化工程技术研究中心,宁夏回医药协同创新中心,宁夏药物创新与仿制药研究重点实验室,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004)(2.宁夏回药现代化工程技术研究中心,宁夏回医药协同创新中心,宁夏药物创新与仿制药研究重点实验室,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004)(2.宁夏回药现代化工程技术研究中心,宁夏回医药协同创新中心,宁夏药物创新与仿制药研究重点实验室,宁夏银川 750004),(1.宁夏医科大学药学院,宁夏银川 750004)(2.宁夏回药现代化工程技术研究中心,宁夏回医药协同创新中心,宁夏药物创新与仿制药研究重点实验室,宁夏银川 750004)
基金项目:宁夏回族自治区科技惠民计划项目(2015KJHM37);宁夏回族自治区重点研发计划项目(2017BY079)
摘    要:本文探讨香杞平脂咀嚼片对高脂血症模型小鼠体重、血脂以及肝功能的影响。选取雄性ICR小鼠60只,随机平均分为6组:正常组(生理盐水),模型组(生理盐水),辛伐他汀组(5 mg/kg),香杞平脂咀嚼片高(2 g/kg)、中(1 g/kg)、低剂量组(0.5 g/kg),除正常组饲喂普通饲料外,其余各组采用饲喂高糖高脂饲料进行造模,实验期间采取经口灌胃给药方式,在6周后测定各项实验指标。此造模方法得到的高脂血症模型对小鼠体重影响不大,而香杞平脂咀嚼片组与模型组相比较能够降低高脂血症小鼠血清中的总胆固醇、低密度脂蛋白、谷草转氨酶和谷丙转氨酶,其最大降幅为28.85%、37.90%、25.08%和42.09%,并且可以升高高密度脂蛋白,最大升幅为73.70%。结果表明香杞平脂咀嚼片具有降血脂和保护肝脏的作用,且此效应在高剂量(2 g/kg)时最为明显。

关 键 词:香杞平脂咀嚼片  高脂血症  降血脂  保肝
收稿时间:2018/7/30 0:00:00

Study on the Lipid-lowering Effect of Xiang Qi Lower Blood Lipids Chewable Tablet
LU Min,CHANG Xiao-jie,ZHANG Wen-jin,LIU Ning,YANG Jia-mei,LIU Yan-hu,MA Xue-qin,YANG Jian-hong,YU Jian-qiang and LI Feng-mei.Study on the Lipid-lowering Effect of Xiang Qi Lower Blood Lipids Chewable Tablet[J].Modern Food Science & Technology,2018,34(11):35-40.
Authors:LU Min  CHANG Xiao-jie  ZHANG Wen-jin  LIU Ning  YANG Jia-mei  LIU Yan-hu  MA Xue-qin  YANG Jian-hong  YU Jian-qiang and LI Feng-mei
Affiliation:(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China),(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China),(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China) (2.Ningxia Hui Medicine Modernization Engineering Technology Research Center, Ningxia Hui Medicine Collaborative Innovation Center, Ningxia Key Laboratory of Drug Innovation and Generic Drug Research, Yinchuan 750004, China),(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China) (2.Ningxia Hui Medicine Modernization Engineering Technology Research Center, Ningxia Hui Medicine Collaborative Innovation Center, Ningxia Key Laboratory of Drug Innovation and Generic Drug Research, Yinchuan 750004, China),(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China) (2.Ningxia Hui Medicine Modernization Engineering Technology Research Center, Ningxia Hui Medicine Collaborative Innovation Center, Ningxia Key Laboratory of Drug Innovation and Generic Drug Research, Yinchuan 750004, China),(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China) (2.Ningxia Hui Medicine Modernization Engineering Technology Research Center, Ningxia Hui Medicine Collaborative Innovation Center, Ningxia Key Laboratory of Drug Innovation and Generic Drug Research, Yinchuan 750004, China),(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China) (2.Ningxia Hui Medicine Modernization Engineering Technology Research Center, Ningxia Hui Medicine Collaborative Innovation Center, Ningxia Key Laboratory of Drug Innovation and Generic Drug Research, Yinchuan 750004, China),(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China) (2.Ningxia Hui Medicine Modernization Engineering Technology Research Center, Ningxia Hui Medicine Collaborative Innovation Center, Ningxia Key Laboratory of Drug Innovation and Generic Drug Research, Yinchuan 750004, China),(1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China) (2.Ningxia Hui Medicine Modernization Engineering Technology Research Center, Ningxia Hui Medicine Collaborative Innovation Center, Ningxia Key Laboratory of Drug Innovation and Generic Drug Research, Yinchuan 750004, China) and (1.College of Pharmacy Ning Xia Medical University, Yinchuan 750004, China) (2.Ningxia Hui Medicine Modernization Engineering Technology Research Center, Ningxia Hui Medicine Collaborative Innovation Center, Ningxia Key Laboratory of Drug Innovation and Generic Drug Research, Yinchuan 750004, China)
Abstract:The effects of Xiang Qi lower blood lipids chewable tablet on body weight, blood lipids and liver function in hyperlipidemia model mice were investigated in this work. Sixty male Institute of Cancer Research mouse were randomly divided into 6 groups: normal group (normal saline), model group (normal saline), simvastatin-positive group (5 mg/kg), and Xiang Qi lower blood lipids chewable tablet high dose (2 g/kg), medium dose (1 g/kg) and low dose (0.5 g/kg) groups. The normal group was fed with normal feed, and the other groups were fed high-sugar and high-fat feed. Oral administration during the experiment, and various experimental indicators were measured after 6 weeks. The hyperlipidemia model obtained with this modeling method has little effect on the body weight of mouse. Compared with model group, total cholesterol, low-density lipoprotein, aspartate aminotransferase and alanine aminotransferase of the hyperlipidemia mouse serum of decreased Xiang Qi lower blood lipids chewable tablet groups with the largest reduce rates of 28.85%, 37.90%, 25.08% and 42.09%, while high-density lipoprotein increased with the highest growing rate of 73.70%. The results demonstrated that Xiang Qi lower blood lipids chewable tablet has the function of hypolipidemicing and protecting liver, and this effect is most obvious in high dose (2 g/kg).
Keywords:Xiang Qi lower blood lipids chewable tablet  hyperlipidemia  hypolipidemic  protect liver
本文献已被 CNKI 等数据库收录!
点击此处可从《现代食品科技》浏览原始摘要信息
点击此处可从《现代食品科技》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号